{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-029167","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.306668+00:00","generated_at":"2026-06-19T21:13:28.684508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru reports Q1 FY2023 net loss of $36.8M; revenue falls 82% to $2.5M","bullets":["Net revenues decreased to $2.5M from $14.1M in prior-year quarter; gross profit fell to $0.7M.","Net loss of $36.8M ($0.46 per share) vs. $6.4M ($0.08) a year ago; operating loss $35.6M.","Cash and equivalents dropped to $46.9M at Dec 31, 2022 from $80.2M at Sep 30, 2022.","Sabizabulin for COVID-19 under review by FDA, EMA, MHRA, TGA, Health Canada and others.","IDWeek data: sabizabulin showed 81.2% relative reduction in deaths in WHO 4 subset (p=0.0090)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-029167","json":"https://secwatch.observer/filing/0001193125-23-029167.json","markdown":"https://secwatch.observer/filing/0001193125-23-029167.md","text":"https://secwatch.observer/filing/0001193125-23-029167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/0001193125-23-029167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/d458190d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:13:28.684508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"933d92c290e2479310f4446f844100d665c4909c","claim":"VERU INC. reported fiscal 2023 first quarter results: revenue $2.5 million, net income $36.8 million, or $0.46 per share.","evidence_excerpt":"with an enlarged prostate experiencing the signs and symptoms of BPH for up to 26 weeks. First Quarter Financial Summary: Fiscal 2023 vs Fiscal 2022 • Net revenues decreased to $2.5 million from $14.1 million • Gross profit decreased to $0.7 million from $11.8 million 2 • Research and development expenses increased to $18.7 million from $10.1 million • Selling,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312523029167/0001193125-23-029167-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023 first quarter"},{"label":"Revenue","value":"$2.5 million"},{"label":"Net income","value":"$36.8 million, or $0.46 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}